Henry Ford + MSU researchers granted $3M from NIH to study HPV-positive head-and-neck cancers

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated.

February 27, 2026

Vol.52 No.08

Drugs & Targets

FDA grants Breakthrough Therapy designation to Rybrevant Faspro in advanced head-and-neck cancer

FDA granted Breakthrough Therapy designation for subcutaneous amivantamab and hyaluronidase-lpuj as a monotherapy for the treatment of adults with head-and-neck squamous cell carcinoma that is recurrent or metastatic and human papillomavirus-unrelated after disease progression on or after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor.

February 20, 2026

Vol.52 No.07

Clinical Roundup

HPV cancer vaccine slows tumor growth, extends survival in animal models

Throughout the past decade, Northwestern University scientists have uncovered a striking principle of vaccine design: Performance depends not only on vaccine components but also on vaccine structure.

February 13, 2026

Vol.52 No.06

Clinical Roundup

Sylvester-led study focuses on rate of failure in head and neck cancer trials

Researchers from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and collaborators analyzed 692 clinical trials launched between 2000 and 2024.

January 23, 2026

Vol.52 No.03

Clinical Roundup

Proton vs. traditional radiation therapy significantly improves survival in head and neck cancers, MD Anderson-led study finds

Patients with oropharyngeal cancers who were treated with proton therapy, compared to traditional radiation therapy saw a significant survival benefit, according to the findings from a phase III trial led by researchers at the University of Texas MD Anderson Cancer Center.

December 19, 2025

Vol.51 No.46

Drugs & Targets

EC approves Keytruda combination for a head-and-neck indication

The European Commission approved Keytruda (pembrolizumab), an anti-PD-1 therapy, as a monotherapy for the treatment of resectable locally advanced head-and-neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumors express PD-L1 with a Combined Positive Score ≥1.

October 31, 2025

Vol.51 No.40

Henry Ford + MSU researchers granted $3M from NIH to study HPV-positive head-and-neck cancers

YOU MAY BE INTERESTED IN

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

FDA grants Breakthrough Therapy designation to Rybrevant Faspro in advanced head-and-neck cancer

HPV cancer vaccine slows tumor growth, extends survival in animal models

Sylvester-led study focuses on rate of failure in head and neck cancer trials

Proton vs. traditional radiation therapy significantly improves survival in head and neck cancers, MD Anderson-led study finds

EC approves Keytruda combination for a head-and-neck indication

Renew today!

Subscriber content

Never miss an issue!

Login